The cancer and fibrosis drug developer's series D round was co-led by investors including Walvax Biotechnology and a fund management vehicle for Sunshine Insurance.
Vaccine developer Walvax Biotechnology has co-led a $105m series D round for Sirnaomics, a US-headquartered company developing treatments for conditions with unmet medical need.
The round was co-led with Sunshine Riverhead Capital, a private equity fund manager for insurance firm Sunshine Insurance, and investment manager Rotating Boulder Fund. It included Sangel Capital, Longmen Capital, HongTao Capital and Alpha Win Capital.
Sirnaomics is working on RNAi medicines to treat diseases including cancer, fibrosis, metabolic diseases and viral infections. It announced positive…
